HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma.

AbstractBACKGROUND:
Osteosarcoma (OS) is a common malignant cancer in children and adolescents and has a cure rate that has not improved in the last two decades. CYT997 (lexibulin) is a novel potent microtubule-targeting agent with various anticancer activities, such as proliferation inhibition, vascular disruption, and cell cycle arrest and apoptosis induction, in multiple cancers. However, the direct cytotoxic mechanisms of CYT997 have not yet been fully characterized.
METHODS:
We evaluated apoptosis and autophagy in human osteosarcomas after treatment with CYT997 and investigated the underlying mechanisms. To explore relationships, we used the reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC), PERK inhibitor GSK2606414, ERO1 inhibitor EN460 and mitochondrial targeted protection peptide elamipretide. BALB/c-nu mice were inoculated with 143B tumor cells to investigate the in vivo effect of CYT997.
RESULTS:
We explored the efficacy and mechanism of CYT997 in osteosarcoma (OS) in vitro and in vivo and demonstrated that CYT997 potently suppresses cell viability and induces apoptosis and autophagy. CYT997 triggered production of ROS and exerted lethal effects via endoplasmic reticulum (ER) stress in OS cells. NAC attenuated these effects. The PERK inhibitor GSK2606414, which can block the ER stress pathway, reduced ROS production and enhanced cell viability. Moreover, activation of ERO1 in the ER stress pathway was responsible for inducing ROS production. ROS produced by the mitochondrial pathway also aggravate ER stress. Protection of mitochondria can reduce apoptosis and autophagy. Finally, CYT997 prominently reduced tumor growth in vivo.
CONCLUSIONS:
This study suggests that CYT997 induces apoptosis and autophagy in OS cells by triggering mutually enhanced ER stress and ROS and may thus be a promising agent against OS.
AuthorsZongyi Wang, Fei Yin, Jing Xu, Tao Zhang, Gangyang Wang, Ming Mao, Zhuoying Wang, Wei Sun, Jing Han, Mengkai Yang, Yafei Jiang, Yingqi Hua, Zhengdong Cai
JournalJournal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 38 Issue 1 Pg. 44 (Jan 31 2019) ISSN: 1756-9966 [Electronic] England
PMID30704503 (Publication Type: Journal Article)
Chemical References
  • CYT997
  • Pyridines
  • Pyrimidines
  • Reactive Oxygen Species
Topics
  • Animals
  • Apoptosis (drug effects)
  • Autophagy
  • Bone Neoplasms (drug therapy, metabolism, pathology)
  • Cell Cycle (drug effects)
  • Cell Proliferation (drug effects)
  • Endoplasmic Reticulum Stress (drug effects)
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mitochondria (drug effects, metabolism, pathology)
  • Osteosarcoma (drug therapy, metabolism, pathology)
  • Pyridines (pharmacology)
  • Pyrimidines (pharmacology)
  • Reactive Oxygen Species (metabolism)
  • Signal Transduction
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: